Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Prostate cancer is the second most common cancer in men worldwide. While clinicians commonly see metastases to the bones and lymph nodes, it may infrequently spread to more uncommon locations. We report an unusual case of an 83-year-old patient with previously treated prostate adenocarcinoma who presents with symptomatic metastases to the testis and brain in the absence of widely disseminated disease. This case report highlights the importance of including metastatic disease in the differential for patients with a history of prostate cancer and a newly discovered mass until an evaluation of the tissue can be performed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553064 | PMC |
| http://dx.doi.org/10.1093/omcr/omx042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis.
Biochem Biophys Rep
June 2025
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Background: SLC16A3, a highly expressed H + -coupled symporter, facilitates lactate transport via monocarboxylate transporters (MCTs), contributing to acidosis. Although SLC16A3 has been implicated in tumor development, its role in tumor immunity remains unclear.
Methods: A pan-cancer analysis was conducted using datasets from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, and Genotype-Tissue Expression projects.
Objective: To determine optimal CT perfusion (CTP) imaging parameters for evaluating the canine prostate and to assess the diagnostic utility of CTP combined with cytopathologic evaluation and B-Raf proto-oncogene (BRAF) gene mutation testing in dogs with prostate adenocarcinoma.
Methods: For this study, 10 male dogs were enrolled, comprising 4 healthy Beagles and 6 client-owned dogs with suspected prostatic neoplasia. Computed tomography perfusion was performed in the healthy dogs using varied contrast agent doses and injection durations.
Prediction of metastasis-free survival in patients with localized prostate adenocarcinoma using primary tumor and lymph node radiomics from pre-treatment PSMA-PET/CT scans.
Radiother Oncol
September 2025
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Purpose: To predict metastasis-free survival (MFS) for patients with prostate adenocarcinoma (PCa) treated with androgen deprivation therapy (ADT) and external radiotherapy using clinical factors and radiomics extracted from primary tumor and node volumes in pre-treatment PSMA PET/CT scans.
Materials/methods: Our cohort includes 134 PCa patients (nodal involvement in 28 patients). Gross tumor volumes of primary tumor (GTVp) and nodes (GTVn) on CT and PET scans were segmented.
The unexpected finding of breast and axillary metastases in a patient with prostate carcinoma.
Radiol Case Rep
November 2025
Department of Clinical and Experimental Medicine, Foggia University School of Medicine, Viale L. Pinto 1, 71122 Foggia, Italy.
We report a rare case of breast and axillary metastases in a 75-year-old man diagnosed with prostate carcinoma. Initially, the patient presented with lower urinary tract symptoms (LUTS) and elevated prostate-specific antigen (PSA) levels. Prostate cancer was confirmed by biopsy and treated with androgen deprivation therapy (ADT) and radiotherapy.
View Article and Find Full Text PDFEvaluation of potential prognostic significance of JUNB in human prostate cancer: a bioinformatic and histopathological study.
J Pathol Transl Med
September 2025
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Background: Prostate cancer is one of the most common malignancies in males worldwide. Serum prostate-specific antigen is a frequently employed biomarker in the diagnosis and risk stratification of prostate cancer; however, it is known for its low predictive accuracy for disease progression. New prognostic biomarkers are needed to distinguish aggressive prostate cancer from low-risk disease.
View Article and Find Full Text PDF